Paper Details

  1. Home
  2. Paper Details

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).

Author: AlranSeverine, BalleyguierCorinne, BecetteVeronique, BourgierCéline, BoussionVéronique, CherelPascal, KerbratPierre, Lavau-DenesSandrine, LemonnierJerome, LereboursFlorence, MartinAnne-Laure, MathieuMarie-Christine, Mouret-FourmeEmmanuelle, Mouret-ReynierMarie-Ange, NabholzJean-Marc, RiveraSofia, SalmonRemy, SigalBrigitte, ThibaultFabienne, TrassardMartine, Venat-BouvetLaurence

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

New treatments for breast cancer in the early 2000s have led to the consideration of using hormone therapy as a pre-surgical treatment for younger women with hormone receptor (HR)-positive breast cancer who are not candidates for breast-conserving surgery. This approach is being explored for women who are too frail for chemotherapy before surgery.
Paper Details　
Original Abstract of the Article :
Treatment strategies for locally advanced breast cancer in elderly patients too frail to receive neoadjuvant chemotherapy and the introduction of new classes of drugs in the early 2000s have led to the consideration of endocrine therapy as a neoadjuvant treatment for younger hormone receptor (HR)-po...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/cncr.30143

データ提供：米国国立医学図書館（NLM）

Neoadjuvant Endocrine Therapy for Breast Cancer: A New Frontier

The field of breast cancer treatment is a constantly evolving landscape. This study explores the use of neoadjuvant endocrine therapy, a novel approach to treating hormone receptor-positive breast cancer in postmenopausal patients. The study focused on the UNICANCER CARMINA 02 French trial, a randomized phase 2 trial investigating the effectiveness of anastrozole and fulvestrant in this patient population.

Endocrine Therapy: A Promising Alternative for Specific Patients

The research found that endocrine therapy may be a viable option for younger patients who are not eligible for primary breast-conserving surgery, potentially offering an alternative to traditional chemotherapy. However, this study was limited in scope and further research is needed to confirm its efficacy and determine its suitability for a wider range of patients.

Health Implications

While this study offers a promising potential treatment option, it is essential to remember that each patient is unique and requires a personalized approach. Consult with your healthcare provider to determine the best treatment plan based on your individual circumstances.

Dr.Camel's Conclusion

This study opens a new chapter in the ongoing quest for effective breast cancer treatments. While endocrine therapy holds promise for certain patients, more research is needed to fully understand its potential and ensure its safe and effective implementation. Ultimately, the journey through breast cancer treatment requires a collaborative effort between patients and healthcare professionals.

Date :
  1. Date Completed 2017-05-25
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27315583

DOI: Digital Object Identifier

10.1002/cncr.30143

Related Literature

Article Analysis
・Effective treatment of breast cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.